地诺孕素与复方口服避孕药用于子宫内膜异位症术后预防复发的成本-效果分析
本研究采用决策树模型,基于中国医疗体系数据,比较地诺孕素(DNG)与复方口服避孕药(COC)用于子宫内膜异位症腹腔镜术后预防复发的成本-效果。基础分析显示DNG组获得0.7493质量调整生命年(QALY),成本1625.49美元;COC组获得0.7346 QALY,成本343.61美元;增量成本效果比为每额外获得1个QALY需87679.89美元,增量净货币效益为-731.39美元。概率敏感性分析提示,在世界卫生组织推荐的37653美元/QALY阈值下,DNG在多数情况下不具有成本-效果。
要点
- DNG组QALY 0.7493、成本1625.49美元;COC组QALY 0.7346、成本343.61美元。
- 增量成本效果比为每额外QALY 87679.89美元,增量净货币效益为-731.39美元。
- 在37653美元/QALY阈值下,DNG多数情况下不具有成本-效果。
核心结论
- 作者分析结果提示,在中国,地诺孕素用于子宫内膜异位症术后预防复发可能不具有成本-效果。
研究设计与样本
- 研究构建决策树模型,基于中国医疗体系数据,比较地诺孕素与复方口服避孕药用于子宫内膜异位症腹腔镜术后预防复发的成本-效果。
主要发现
- 基础分析显示,地诺孕素组获得0.7493质量调整生命年(QALY),成本为1625.49美元;复方口服避孕药组获得0.7346 QALY,成本为343.61美元。
- 增量成本效果比为每额外获得1个QALY需87679.89美元,地诺孕素治疗的增量净货币效益为-731.39美元。
- 概率敏感性分析提示,在与世界卫生组织推荐一致的37653美元/QALY阈值下,地诺孕素在多数情况下不具有成本-效果。
临床怎么用
- 作者分析结果提示,地诺孕素用于中国子宫内膜异位症术后预防复发可能不具有成本-效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To assess the cost-effectiveness of different strategies, including the dienogest (DNG) and combined oral contraceptives (COC) therapy, for the prevention of endometriosis recurrence after surgery. DESIGN: A decision tree model was created. The analysis was based on data from a healthcare provider in China. Model inputs were derived from published data. The end points included incremental cost effectiveness ratio, net monetary benefit (NMB), and incremental NMB associated with prevention of recurrence. The uncertainty was assessed through one way and probabilistic sensitivity analysis. The Consolidated Health Economic Evaluation Reporting Standards 2022 checklist was used to assess quality of the reporting. SETTING: China healthcare system. PATIENTS: Individuals undergoing laparoscopic surgery for endometriosis. INTERVENTIONS: DNG vs COC. MEASUREMENTS AND MAIN RESULTS: The base case analysis showed that hormone supression via DNG resulted in 0.7493 quality-adjusted life years (QALYs) at a cost of $1625.49 compared with COC, which resulted in 0.7346 QALYs at a cost of $343.61. The incremental cost effectiveness ratio was $87 679.89 per additional QALY gained and the DNG treatment was associated with an incremental NMB of -$731.39. Probabilistic sensitivity analysis indicated that DNG is not cost-effective in most cases at a threshold consistent with World Health Organisation recommendations of $37 653/QALY. CONCLUSION: The result of our present analysis suggests that the DNG might not be cost-effective for the prevention of endometriosis recurrence after surgery in China.
引用
- Zhang Z, Wang X, Wang L, et al. Cost-effectiveness Analysis of Dienogest Compared with Combined Oral Contraceptives after Surgery for Endometriosis. J Minim Invasive Gynecol. 2022. PMID: 36596391. doi:10.1016/j.jmig.2022.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。